Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (D07AC) — coverage varies; not interchangeable

  • Amcinonide (Cyclocort): general benefit, Not a benefit
  • Beclomethasone dipropionate (Propaderm): general benefit
  • Betamethasone dipropionate (Diprosone): general benefit
  • Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit
  • Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit
  • Fluocinonide (Lyderm): general benefit, Not a benefit

8 more in the class list below

Diprolene · DIN 00629367 · 0.05% · Oint

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diprolene · DIN 00629367 Manufacturer: Organon Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2023-08-08 · brand DIPROLENE · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 %/W/W · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Diprolene: Formulary list price $0.5186/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5186 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6529 · Verify on the e-Formulary ↗ (DIN 00629367)

Source record
DIN 00629367: Diprolene Raw flags: sec3=Y Item: 840600094; group id 837; item number 2034; lccId None; manufacturer id OCI Source form: Oint; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.5186; ministry $0.5186 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00629367 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6529
Interchangeable products
Ratio-Topilene · DIN 00849669 · $0.5186
Shortage status: resolved shortage (ended 2026-02-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00629367
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ratio-Topilene · DIN 00849669 · 0.05% · Oint

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ratio-Topilene · DIN 00849669 Manufacturer: Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2017-11-28 · brand TEVA-TOPILENE · ATC D07AC01 BETAMETHASONE · form Ointment · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05 % · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Ratio-Topilene: Formulary list price $0.5186/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5186 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10940 · Verify on the e-Formulary ↗ (DIN 00849669)

Source record
DIN 00849669: Ratio-Topilene Raw flags: sec3=Y Item: 840600094; group id 837; item number 2034; lccId None; manufacturer id RPH Source form: Oint; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.5186; ministry $0.5186 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00849669 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10940 Therapeutic Notes (formulary) No more than 50 grams per week of ultrapotent steroids for a maximum of 2 weeks is recommended.
Interchangeable products
Diprolene · DIN 00629367 · $0.5186
Shortage status: active shortage (reported 2024-08-28, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00849669
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered

Matched class: 84:06 Anti-Inflammatory

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:06 Anti-Inflammatory

AMCINONIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.1% · Cr

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 0.025% · Cr, Oint

BETAMETHASONE DIPROPIONATE

· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint

BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE

· 2 products · General benefit · strengths: 0.05% · Cr

BETAMETHASONE VALERATE

· 19 products · Listed, not a benefit (7), General benefit (12) · strengths: 0.05%, 0.1% · Cr, Lot, Oint, Scalp Lot

FLUOCINONIDE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 0.05% · Cr, Emol Cr, Gel, Oint

HALOBETASOL PROPIONATE

· 1 products · General benefit · strengths: 0.01% w/w · Lot

MOMETASONE FUROATE

· 6 products · General benefit · strengths: 0.1% · Cr, Lot, Oint

CLOBETASOL PROPIONATE

· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp

DESONIDE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.05% · Cr, Oint

HYDROCORTISONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.5%, 1% · Oint

HYDROCORTISONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06 and 5 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:28 Keratolytic Agents, 84:36 Miscellaneous Skin and Mucous Membrane Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: the inflammatory manifestations of or psoriasis and corticosteroid-responsive dermatoses
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE · General benefit INDICATIONS AND CLINICAL USE TEVA-TOPILENE is indicated for the relief of the inflammatory manifestations of resistant or severe psoriasis and corticosteroid-responsive dermatoses. PM: https://pdf.hres.ca/dpd_pm/00047893.PDF; date October 16, 2018; DIN 00849650; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USES DIPROLENE® is indicated for the relief of the inflammatory manifestations of resistant or severe psoriasis and corticosteroid-responsive dermatoses. https://pdf.hres.ca/dpd_pm/00060715.PDF PM date: April 13, 2021 Source product: DIPROLENE; DIN 00629367; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Ratio-Topilene · DIN 00849669 Shortage status: active shortage (reported 2024-08-28, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00849669

Check this DIN again